SAMIR GUPTA: Open Payments
NPI 1861457178 · VALPARAISO, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$804 in 31 payments from 10 companies in 2025. Trend: 2023 $297 · 2024 $204 · 2025 $804
Food & beverage: $692Education: $111
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 7 | $198 |
| Otsuka America Pharmaceutical, Inc. | 5 | $121 |
| Teva Pharmaceuticals USA, Inc. | 1 | $111 |
| Lundbeck LLC | 4 | $74 |
| Janssen Pharmaceuticals, Inc | 3 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $58 |
| Supernus Pharmaceuticals, Inc. | 2 | $49 |
| Alkermes, Inc. | 2 | $32 |
| Corium, LLC | 2 | $27 |
Products named: FANAPT, ABILIFY ASIMTUFII, ABILIFY MAINTENA, INVEGA SUSTENNA, COBENFY, CAPLYTA, Qelbree, ARISTADA.
Industry payments across IN — which companies pay providers there.
